Monoclonal antibody therapy with ciclosporin and steroids in nonmatched cadaveric renal transplants by Gordon, RD et al.
Nephron 
Editors: G.M. Berlyne, Brooklyn, N.Y.; S. Giovannetti, Pisa 
Reprint 
Publisher: S.Karger AG, Basel 
Printed in Switzerland 
Transplantation Therapeutics: Monoclonal Antibody Symposium and Workshop, Miami, Fla., 1986 
Nephron 46: supp!.l, pp. 56-59 (1987) 
© 1987 S. Karger AG, Basel 
0028-2766/87/0467 -0056$2. 75/0 
Monoclonal Antibody Therapy with Ciclosporin and Steroids in 
Nonmatched Cadaveric Renal Transplants 1 
Rohert D. Gordon, Thomas E. Starzl, John J. Fung, Shunzaburo Iwatsuki, Carlos O. Esquivel, Andreas Tzakis, 
Satoru Todo 
Department of Surgery, University Health Center of Pittsburgh, University of Pittsburgh, and the Veterans Administration Medical 
Center, Pittsburgh, Pa, USA 
Key Words. Kidney transplantation· Allograft rejection· Immunosuppression. Monoclonal antibody 
Abstract. Thirty-six ciclosporin-prednisone-treated recipients of nonmatched cadaver renal allografts were given a 
course of Orthoclone OKT3 monoclonal antibody for steroid-resistant cell-mediated rejection. Although side effects 
were common, only 2 patients had to be withdrawn from therapy and there were no deaths related to therapy. 
Twenty-three (63.9%) allografts were rescued with OKT3 therapy and 21 (58.3%) of the grafts have continued to 
function well. We conclude that OKT3 is an effective agent for the treatment of steroid-resistant cell-mediated 
rejection and that rebound rejection can be prevented in most patients if adequate therapy with ciclosporin-predni-
sone is maintained. 
Introduction 
Antilymphocyte globulin for the treatment of steroid-
resistant rejection was introduced into clinical practice 
by Starzl et al. [I] and its value has been proved in the 
treatment of steroid-resistant allograft rejection. The lim-
itations of therapy with this heterologous polyclonal 
agent are summarized by Fung et al. [2] elsewhere in this 
symposium. Orthoclone OKT3 is a monoclonal reagent 
directed against a specific T-cell antigen receptor com-
plex known to be important in both antigen recognition 
and T-cell activation [3, 4]. The development of such a 
refined biologic product offers an attractive alternative to 
the treatment of acute cellular allograft rejection with 
conventional antilymphocyte preparations. 
The first successful clinical trials with OKT3, which 
were conducted by Cosimi et al. [5, 6] at the Massachu-
setts General Hospital, provided convincing evidence of 
the increased effectiveness of this agent compared with 
traditional treatment with high-dose steroids. However, 
there was a significant incidence of recurrent rejection 
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after resumption of maintenance therapy with azathio-
prine and prednisone. 
Since 1981, ciclosporin low-dose prednisone therapy 
has been the standard form of immunosuppression for 
cadaveric renal transplants at the University of Pitts-
burgh. In August 1985, we began a pilot trial of OKT3 
therapy for the treatment of steroid-resistant rejection 
in cadaveric renal and hepatic allografts under ciclo-
sporin-steroid therapy. We report here our results for the 
first 36 consecutive renal allograft recipients treated in 
this trial. 
Materials and Methods 
Case Material 
Between August 15, 1984, and December 15, 1985,40 recipients of 
cadaveric renal allografts were treated with OKT3 monoclonal 
antibody. Four of the patients also received a simultaneous pan-
creas transplant, and they are excluded from this report. Thirty-six 
recipients of a renal allograft alone have been followed for 2-20 
months since transplantation. 
The 36 patients included in this series ranged in age from 9 to 63 
years (mean 36.9 ± 13.5 SD). There were 22 males and 14 females. 
Twenty-three patients received a primary graft and 13 patients 
received a second graft. The causes of renal failure were known in all 
but 7 patients and are summarized in table I. There were 7 diabetics 
in the series. 
